Yichun

Researchers are studying the effects of normobaric oxygen (NBO) therapy on patients who have experienced an acute ischemic stroke (AIS) and are transferred for endovascular thrombectomy (EVT). The goal is to assess the safety and effectiveness of NBO in improving functional outcomes three months after stroke. Stroke is a major cause of death and disability worldwide, and while treatments like mechanical thrombectomy can improve blood flow, less than half of patients with large vessel occlusion achieve good recovery. NBO offers potential brain protection by improving oxygen delivery to affected areas and reducing damage through multiple mechanisms. Participants will receive either inhaled 100% oxygen (NBO) or best medical care without NBO. The study focuses on patients transferred for EVT who meet specific stroke severity and imaging criteria. NBO treatment is delivered through oxygen inhalation, aiming to increase oxygen availability to the brain before reperfusion. The study is conducted in a Phase 3 setting and compares outcomes between those receiving NBO and those receiving standard care. During the study, participants will be monitored for disability levels using the modified Rankin scale at 90 days and one year after treatment. Assessments include neurological exams and imaging to confirm stroke details and severity. Researchers will also track safety and functional outcomes to evaluate the impact of NBO therapy. Participants are followed for at least three months after randomization to observe recovery and potential benefits.

Breast cancer is the most common cancer among women worldwide and carries a high risk of death. Around 5% to 10% of breast cancer cases are inherited, linked to mutations in genes like BRCA1, BRCA2, and PALB2. Women with these genetic mutations have a high risk of developing breast cancer and a significantly increased chance of developing cancer in the opposite breast after an initial diagnosis. While removal of the opposite breast is often recommended, many patients decline this surgery due to concerns about surgical risks, complications, and effects on body image and sexuality. This research evaluates the use of preventive radiation therapy to the opposite breast in women with BRCA1, BRCA2, or PALB2 mutations who have breast cancer. The radiation treatment involves daily sessions, five days a week, over 5 to 6 weeks, delivering a total dose of 45 to 50 Gy. The goal is to reduce the risk of cancer developing in the opposite breast by eliminating microscopic tumor cells that might already exist. The study compares this approach to data from traditional opposite breast removal surgery. Participants will undergo radiation therapy to the opposite breast and be closely monitored for up to 10 years to observe the occurrence of new breast cancer in that breast. Assessments include imaging tests like MRI, as well as evaluations of treatment safety and side effects. Researchers aim to determine whether preventive radiation can lower the risk of cancer in the opposite breast and offer an alternative to surgery with less impact on patients' quality of life.